Amgen (NasdaqGS:AMGN) Gains FDA Approval For UPLIZNA In Treating IgG4-Related Disease
Amgen (NasdaqGS:AMGN) experienced a significant 18.62% price increase over the last quarter, coinciding with the recent FDA ...
US FDA approves Amgen's Uplizna as first treatment for rare immune disorder
The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...
Fierce Pharma8h
Amgen wins key rare disease nod for Uplizna, checking off one goal in expansion push
With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth ...
Asianet Newsable on MSN8h
Amgen Stock Edges Higher After Uplizna Becomes First FDA-Approved Treatment For Immune-Mediated Disorder – Retail Gets More Bullish
Shares of medicine manufacturer Amgen Inc (AMGN) are in the spotlight on Friday after it announced that the U.S. Food and ...
BioSpace10h
Amgen Wins Expansion for Uplizna as First Drug for IgG4-Related Disease
The FDA approved Amgen ’s anti-CD19 therapy Uplizna Thursday for use in patients with IgG4-related disease. Uplizna is the ...
Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains
Shares of Amgen Inc. AMGN rallied 1.36% to $309.85 Thursday, on what proved to be an all-around dismal trading session for ...
Explore more
Amgen, Sabra Health Care And A Financial Stock On CNBC's 'Final Trades'
On CNBC's “ Halftime Report Final Trades ,” Jenny Van Leeuwen Harrington of Gilman Hill Asset Management, LLC said Sabra ...
1AMGN : FDA Approves Amgen's Uplizna As First Drug For Chronic Immune-Mediated...
The FDA approved Amgen's Uplizna as the first treatment for IgG4-RD. The decision is backed by the MITIGATE trial, showing reduced flares and sustained efficacy.
US FDA approves expanded use of Amgen's rare disease drug
The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...
PMLive11h
Amgen’s Uplizna approved by FDA as first treatment for rare disease IgG4-RD
Amgen’s Uplizna (inebilizumab-cdon) has been approved by the US Food and Drug Administration (FDA) as the first treatment for ...
The Pharma Letter8h
Amgen’s Uplizna first FDA-approved drug for Ig4A-RD
The US Food and Drug Administration (FDA) has approved Uplizna (inebilizumab-cdon) as the first and only treatment for adults ...
Zacks.com on MSN1d
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts
Amgen (AMGN) concluded the recent trading session at $310.09, signifying a +1.44% move from its prior day's close.